Cubist Inks Deal To Buy Trius, Optimer For Up To $1.6B

Law360, Los Angeles (July 30, 2013, 7:44 PM EDT) -- Cubist Pharmaceuticals Inc. said Tuesday it would acquire all shares of Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc. in two transactions worth up to $1.62 billion, boosting the company’s leadership in the acute care hospital market.

Cubist said it would pay up to $818 million for Trius, a biopharmaceutical company that brings its highly complementary, late-stage antibiotic candidate tedizolid phosphate, and up to $801 million for Jersey City, N.J.-based Optimer, a global biopharmaceutical company currently focused on commercializing its antibiotic product DIFICID, or fidaxomicin, in the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.